Experimental peptide · Reviewed August 16, 2026
Ipamorelin: Human Evidence, FDA Status, and Safety
Ipamorelin has real human growth-hormone pharmacology, but the evidence is far narrower than the anti-aging, recovery, sleep, or body-composition claims used to market it. One commonly cited “selectivity” paper is preclinical, not human.
Unapproved-drug notice
Ipamorelin is not an FDA-approved finished drug product. Clinic availability, a compounded preparation, or “research use only” labeling does not establish FDA approval, broad clinical effectiveness, product quality, or long-term safety [1,2].
Affiliate disclosure
Some pages may include affiliate links. If you buy through those links, The Hippie Scientist may earn a commission at no additional cost to you. Affiliate relationships do not change evidence ratings, safety warnings, product-quality criteria, or editorial conclusions.
Read our affiliate and editorial policyWhat Is Ipamorelin?
Ipamorelin is a synthetic ghrelin-receptor agonist and growth-hormone secretagogue. Its early selectivity reputation came from preclinical experiments in rat pituitary cells, rats, and swine—not from a broad human safety program [3]. Human volunteer data later confirmed that ipamorelin can produce an episodic GH response after intravenous administration [4].
What the Evidence Can Show
| Question | Best current evidence | What it supports | Main boundary |
|---|---|---|---|
| Is ipamorelin selectively GH-releasing? | Rat/swine pharmacology [3] | Preclinical mechanism/selectivity signal | Not a human safety conclusion |
| Does ipamorelin raise GH in humans? | Human PK/PD dose-escalation study [4] | Episodic GH release and pharmacokinetic characterization | Does not establish recovery, sleep, anti-aging, or physique benefit |
| Has a controlled clinical outcome trial been done? | Randomized placebo-controlled phase 2 postoperative-ileus trial [5] | Direct patient-outcome evidence exists | Key and secondary efficacy outcomes were not significantly different from placebo |
| Are CJC-1295 + ipamorelin stacks validated? | No robust replicated controlled outcome program identified | Mechanistic rationale only | Not an established combination therapy |
| Are broad wellness outcomes proven? | Evidence gap | No reliable conclusion | Marketing claims substantially outrun direct human outcomes |
FDA & Compounding Status — Checked August 16, 2026
Ipamorelin is not FDA-approved as a finished drug product. FDA's current significant-safety-risk page lists ipamorelin acetate in category 2 under the 503B interim policy and also includes it in the withdrawn-nomination section [1].
FDA's compounding categories and bulks-list decisions are specific regulatory processes. A clinic offering, prescription, compounded vial, or peptide-market listing should not be translated into a claim that ipamorelin is FDA-approved or broadly authorized for human use [1,2].
Safety Uncertainty
- FDA flags potential immunogenicity, aggregation, peptide-impurity, and characterization concerns for compounded ipamorelin acetate [1].
- FDA reports serious adverse events, including death, in an intravenous ipamorelin study conducted for gastric-motility purposes. FDA separately states that safety information is lacking for certain other injectable routes [1].
- The published 2014 randomized postoperative-ileus trial reported short-term tolerability but did not show a significant efficacy advantage over placebo; that trial should not be used to establish long-term safety or broad wellness benefit [5].
- The preclinical selectivity paper cannot be converted into a blanket statement that ipamorelin is a “clean” or low-risk secretagogue in humans [3].
Bottom Line
Ipamorelin can trigger GH release in humans, but the evidence does not establish the broad anti-aging, recovery, sleep, fat-loss, or physique outcomes commonly marketed. Its classic selectivity study is preclinical, the available controlled clinical trial was neutral on efficacy, and FDA continues to flag important compounding safety uncertainties.
Source ledger
References
5 sources
- 01FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current ipamorelin acetate entry. Source →
- 02FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Current framework and rulemaking process. Source →
- 03Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. Preclinical rat and swine pharmacology. PMID 9849822. PubMed →
- 04Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. PMID 10496658. PubMed →
- 05Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014. PMID 25331030. PubMed →